Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.63 |
| ▸ | FNTA | P49354 | 4/20 | 0.61 |
| ▸ | FNTB | P49356 | 4/20 | 0.61 |
| ▸ | SQLE | Q14534 | 7/20 | 0.56 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816109 | 0.88 | KMT2A (0.66) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2813737 | 0.87 | KMT2A (0.70) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2814621 | 0.87 | KMT2A (0.70) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3671529 | 0.86 | FNTA (0.60) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3671531 | 0.86 | FNTA (0.60) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL13129961 | 0.82 | KMT2A (0.74) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geraniol SCHEMBL16346237 | 0.81 | KMT2A (0.83) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| Geraniol SCHEMBL16346238 | 0.81 | KMT2A (0.83) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL27539247 | 0.81 | KMT2A (0.65) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL9474308 | 0.80 | KMT2A (0.70) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | BHMT, BHMT2, GNMT | KMT2A 601/4885ALOX15 527/4885MAPT 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.